These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15330831)

  • 1. Complete but transient relief of chronic cluster headache with mycophenolate mofetil.
    Rozen TD
    Headache; 2004 Sep; 44(8):818-20. PubMed ID: 15330831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
    Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
    Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil].
    Noroña B; Valentín M; Gutiérrez E; Praga M
    Nefrologia; 2004; 24(1):79-82. PubMed ID: 15083963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using mycophenolate mofetil in steroid-resistant nephrotic syndrome.
    Ganji MR
    Iran J Kidney Dis; 2012 Sep; 6(5):323-5. PubMed ID: 22976252
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil.
    Moudgil A; Przygodzki RM; Kher KK
    Pediatr Nephrol; 2006 Feb; 21(2):281-5. PubMed ID: 16362392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent.
    Megahed M; Schmiedeberg S; Becker J; Ruzicka T
    J Am Acad Dermatol; 2001 Aug; 45(2):256-9. PubMed ID: 11464188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
    Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Bonsmann G; Luger TA
    Arch Dermatol; 2007 Dec; 143(12):1536-42. PubMed ID: 18087004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders.
    Baltatzis S; Tufail F; Yu EN; Vredeveld CM; Foster CS
    Ophthalmology; 2003 May; 110(5):1061-5. PubMed ID: 12750115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis.
    Mori M; Nwaogwugwu U; Akers GR; McGill RL
    Clin Nephrol; 2013 Jul; 80(1):67-71. PubMed ID: 23803597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of linear IgA disease with mycophenolate mofetil as a corticosteroid sparing agent.
    Talhari C; Mahnke N; Ruzicka T; Megahed M
    Clin Exp Dermatol; 2005 May; 30(3):297-8. PubMed ID: 15807696
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.
    Gorson KC; Amato AA; Ropper AH
    Neurology; 2004 Aug; 63(4):715-7. PubMed ID: 15326250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil therapy for inflammatory eye disease.
    Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
    Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
    Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis.
    Edge JC; Outland JD; Dempsey JR; Callen JP
    Arch Dermatol; 2006 Jan; 142(1):65-9. PubMed ID: 16415388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case reports: nodular vasculitis responsive to mycophenolate mofetil.
    Taverna JA; Radfar A; Pentland A; Poggioli G; Demierre MF
    J Drugs Dermatol; 2006; 5(10):992-3. PubMed ID: 17373149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil for the treatment of scleritis.
    Sen HN; Suhler EB; Al-Khatib SQ; Djalilian AR; Nussenblatt RB; Buggage RR
    Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.
    Kirklin JK; Bourge RC; Naftel DC; Morrow WR; Deierhoi MH; Kauffman RS; White-Williams C; Nomberg RI; Holman WL; Smith DC
    J Heart Lung Transplant; 1994; 13(3):444-50. PubMed ID: 8061021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent.
    Tran MM; Anhalt GJ; Barrett T; Cohen BA
    J Am Acad Dermatol; 2006 Apr; 54(4):734-6. PubMed ID: 16546607
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
    Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
    Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.